

Karin A. HUGHES, VP Clinical & Regulatory Strategy,  
Astute Medical, Inc –  
Fabien ROY, Counsel, Hogan Lovells

23-25 JAN.  
2018  
—  
The EGG  
BRUSSELS

# MDR and IVDR : Challenges and opportunities for SMEs and start-ups



A MedTech Europe event

## The MedTech Forum

bringing HealthTech stakeholders together

Hogan  
Lovells

# Objectives

- Identify key issues and opportunities for start-up and SMEs
- Obtain your feedbacks and comments

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

# Challenges

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

# Challenges

- Understanding the changes and the timelines
- Determine the appropriate budget to support transition to the new Regulations
- Obtain the management's support to ensure the transition
- Identify appropriate resources:
  - Internal: hiring new employees
  - External: authorised representative, notified body, consultants/experts
- Determine if clinical/performance data will be sufficient/if new clinical data is required



# Challenges

- Take the right strategic decisions for the company
- Change to the business model: EU first?
- In light of the transition provisions in the Regulation, is it a good time to launch a new product on the EU market?
- Assessing new obligations for economic operators (e.g. Legal manufacturer in Switzerland permitted?)
- Understanding the consequences for the ROW
- Plan and implement plan according to agreed timeline
- Internal discipline
- External factors (NB, implementing/delegated Acts, guidance, Brexit, harmonised standards...)

# Opportunities

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

# Opportunities

- Rationalise portfolio
- Reevaluate the priorities of the companies
- Business opportunities – growing through acquisition?
- Market opportunities – taking advantage of competitors not ready for the MDR/IVDR (e.g. in tenders)
- A lighter transition process for SMEs and start-ups?
  - Easier to adapt for new/small businesses
- Implement now changes which are straightforward (e.g. QMS, labeling)

# Other Challenges and Opportunities?

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.



Thank you

Questions

[khughes@astutemedical.com](mailto:khughes@astutemedical.com)

[fabien.roy@hoganlovells.com](mailto:fabien.roy@hoganlovells.com)



2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.